Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group

Fernö, Mårten LU ; Baldetorp, Bo LU ; Borg, Åke LU ; Brouillet, J P ; Olsson, Håkan LU orcid ; Rochefort, H ; Sellberg, Gunilla LU ; Sigurdsson, H and Killander, Dick LU (1994) In European Journal of Cancer 30a(14). p.2042-2048
Abstract
Cathepsin D is a lysosomal protease implicated in cancer metastasis. Its concentration in breast tumours has also been shown to be of prognostic importance, although to what extent this is subject to lymph node status, the use of adjuvant therapy and menopausal status has not been clearly evaluated. At a cut-off level of 45 pmol/mg protein (61% of the 623 samples were classified as high cathepsin D tumours; immunoradiometric assay), we found cathepsin D to be of prognostic importance only among breast cancer patients with lymph node-positive (N+) disease not treated with adjuvant tamoxifen. When the series was stratified according to cathepsin D content of their tumours, progesterone receptor (PgR) status and lymph node involvement,... (More)
Cathepsin D is a lysosomal protease implicated in cancer metastasis. Its concentration in breast tumours has also been shown to be of prognostic importance, although to what extent this is subject to lymph node status, the use of adjuvant therapy and menopausal status has not been clearly evaluated. At a cut-off level of 45 pmol/mg protein (61% of the 623 samples were classified as high cathepsin D tumours; immunoradiometric assay), we found cathepsin D to be of prognostic importance only among breast cancer patients with lymph node-positive (N+) disease not treated with adjuvant tamoxifen. When the series was stratified according to cathepsin D content of their tumours, progesterone receptor (PgR) status and lymph node involvement, adjuvant tamoxifen was found to have a significant beneficial effect only among patients with N+ and PgR-positive breast cancer whose tumours had a high cathepsin D content. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Cancer
volume
30a
issue
14
pages
2042 - 2048
publisher
Elsevier
external identifiers
  • pmid:7857700
ISSN
1879-0852
language
English
LU publication?
yes
id
b62a31d6-113d-4ea1-9232-49c405105d1d (old id 1107813)
date added to LUP
2016-04-01 12:08:59
date last changed
2019-03-08 03:12:25
@article{b62a31d6-113d-4ea1-9232-49c405105d1d,
  abstract     = {{Cathepsin D is a lysosomal protease implicated in cancer metastasis. Its concentration in breast tumours has also been shown to be of prognostic importance, although to what extent this is subject to lymph node status, the use of adjuvant therapy and menopausal status has not been clearly evaluated. At a cut-off level of 45 pmol/mg protein (61% of the 623 samples were classified as high cathepsin D tumours; immunoradiometric assay), we found cathepsin D to be of prognostic importance only among breast cancer patients with lymph node-positive (N+) disease not treated with adjuvant tamoxifen. When the series was stratified according to cathepsin D content of their tumours, progesterone receptor (PgR) status and lymph node involvement, adjuvant tamoxifen was found to have a significant beneficial effect only among patients with N+ and PgR-positive breast cancer whose tumours had a high cathepsin D content.}},
  author       = {{Fernö, Mårten and Baldetorp, Bo and Borg, Åke and Brouillet, J P and Olsson, Håkan and Rochefort, H and Sellberg, Gunilla and Sigurdsson, H and Killander, Dick}},
  issn         = {{1879-0852}},
  language     = {{eng}},
  number       = {{14}},
  pages        = {{2042--2048}},
  publisher    = {{Elsevier}},
  series       = {{European Journal of Cancer}},
  title        = {{Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group}},
  volume       = {{30a}},
  year         = {{1994}},
}